Literature DB >> 19187761

Structural basis for the requirement of additional factors for MLL1 SET domain activity and recognition of epigenetic marks.

Stacey M Southall1, Poon-Sheng Wong, Zain Odho, S Mark Roe, Jon R Wilson.   

Abstract

The mixed-lineage leukemia protein MLL1 is a transcriptional regulator with an essential role in early development and hematopoiesis. The biological function of MLL1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl-terminal SET domain. We have determined the crystal structure of the MLL1 SET domain in complex with cofactor product AdoHcy and a histone H3 peptide. This structure indicates that, in order to form a well-ordered active site, a highly variable but essential component of the SET domain must be repositioned. To test this idea, we compared the effect of the addition of MLL complex members on methyltransferase activity and show that both RbBP5 and Ash2L but not Wdr5 stimulate activity. Additionally, we have determined the effect of posttranslational modifications on histone H3 residues downstream and upstream from the target lysine and provide a structural explanation for why H3T3 phosphorylation and H3K9 acetylation regulate activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19187761     DOI: 10.1016/j.molcel.2008.12.029

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  114 in total

Review 1.  Keeping it in the family: diverse histone recognition by conserved structural folds.

Authors:  Kyoko L Yap; Ming-Ming Zhou
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-10-06       Impact factor: 8.250

2.  Charge-based interaction conserved within histone H3 lysine 4 (H3K4) methyltransferase complexes is needed for protein stability, histone methylation, and gene expression.

Authors:  Douglas P Mersman; Hai-Ning Du; Ian M Fingerman; Paul F South; Scott D Briggs
Journal:  J Biol Chem       Date:  2011-12-06       Impact factor: 5.157

3.  Structural analysis of the core COMPASS family of histone H3K4 methylases from yeast to human.

Authors:  Yoh-hei Takahashi; Gerwin H Westfield; Austin N Oleskie; Raymond C Trievel; Ali Shilatifard; Georgios Skiniotis
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-07       Impact factor: 11.205

4.  Bioinformatic Identification of Novel Methyltransferases.

Authors:  Tanya Petrossian; Steven Clarke
Journal:  Epigenomics       Date:  2009-10-01       Impact factor: 4.778

5.  The structure of NSD1 reveals an autoregulatory mechanism underlying histone H3K36 methylation.

Authors:  Qi Qiao; Yan Li; Zhi Chen; Mingzhu Wang; Danny Reinberg; Rui-Ming Xu
Journal:  J Biol Chem       Date:  2010-12-31       Impact factor: 5.157

6.  Dimerization of a viral SET protein endows its function.

Authors:  Hua Wei; Ming-Ming Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-11       Impact factor: 11.205

Review 7.  Touch, act and go: landing and operating on nucleosomes.

Authors:  Valentina Speranzini; Simona Pilotto; Titia K Sixma; Andrea Mattevi
Journal:  EMBO J       Date:  2016-01-19       Impact factor: 11.598

8.  Discovery of Potent Small-Molecule Inhibitors of MLL Methyltransferase.

Authors:  Ting-Rong Chern; Liu Liu; Elyse Petrunak; Jeanne A Stuckey; Mi Wang; Denzil Bernard; Haibin Zhou; Shirley Lee; Yali Dou; Shaomeng Wang
Journal:  ACS Med Chem Lett       Date:  2020-05-14       Impact factor: 4.345

9.  A non-active-site SET domain surface crucial for the interaction of MLL1 and the RbBP5/Ash2L heterodimer within MLL family core complexes.

Authors:  Stephen A Shinsky; Michael Hu; Valarie E Vought; Sarah B Ng; Michael J Bamshad; Jay Shendure; Michael S Cosgrove
Journal:  J Mol Biol       Date:  2014-03-27       Impact factor: 5.469

10.  ASH2L regulates ubiquitylation signaling to MLL: trans-regulation of H3 K4 methylation in higher eukaryotes.

Authors:  Lipeng Wu; Shirley Y Lee; Bo Zhou; Uyen T T Nguyen; Tom W Muir; Song Tan; Yali Dou
Journal:  Mol Cell       Date:  2013-02-28       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.